Barinthus Biotherapeutics plc (FRA:2AB)
Germany · Delayed Price · Currency is EUR 0.5550
-0.0250 (-4.31%)
Last updated: May 18, 2026, 8:05 AM CET
Barinthus Biotherapeutics Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
14
Market Cap
23.89M EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 14.97M | 14.17M | 1,766.46% |
| Dec 31, 2023 | 802.00K | -43.90M | -98.21% |
| Dec 31, 2022 | 44.70M | 44.44M | 16,580.22% |
| Dec 31, 2021 | 268.00K | -4.55M | -94.44% |
| Dec 31, 2020 | 4.82M | -2.02M | -29.57% |
| Dec 31, 2019 | 6.85M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| edding AG | 144.91M |
| ACCENTRO Real Estate AG | 77.32M |
| learnd SE | 68.30M |
| Hyrican Informationssysteme Aktiengesellschaft | 24.26M |
| tick Trading Software AG | 9.15M |
| Weng Fine Art AG | 2.48M |
| Rubean AG | 1.78M |
| Petro Matad | 1.73M |
Barinthus Biotherapeutics News
- 17 days ago - Barinthus Bio Reports First Quarter 2026 Financial Results and Updates on Corporate Developments - GlobeNewsWire
- 2 months ago - Barinthus Biotherapeutics reports FY25 EPS ($1.64) vs ($1.55) last year - TheFly
- 5 months ago - Barinthus Biotherapeutics announces update on Phase 1 trial of VTP-1000 - TheFly
- 6 months ago - Barinthus Biotherapeutics price target raised to $4 from $3 at H.C. Wainwright - TheFly
- 6 months ago - Barinthus Biotherapeutics reports Q3 EPS (36c) vs (21c) last year - TheFly
- 7 months ago - ChemDiv Continues R&D Services Support for Clywedog Therapeutics Following Merger with Barinthus Therapeutics - PRNewsWire
- 8 months ago - BARINTHUS BIOTHERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Barinthus Biotherapeutics plc - BRNS - Business Wire
- 8 months ago - Barinthus Biotherapeutics to Combine with Clywedog Therapeutics to Target Metabolic and Autoimmune Diseases - GlobeNewsWire